Injecting drugs substantially increases the risk of hepatitis C virus (HCV) infection and is common in the homeless and prisoners. Capturing accurate data on disease prevalence within these groups is challenging but is essential to inform strategies to reduce HCV transmission. The aim of this study was to estimate the prevalence of HCV in these populations. We conducted a cross-sectional study between May 2011 and June 2013 in London and, using convenience sampling, recruited participants from hostels for the homeless, drug treatment services and a prison. A questionnaire was administered and blood samples were tested for hepatitis C. We recruited 491 individuals who were homeless (40.7%), 205 drug users (17%) and 511 prisoners (42.3%). Eight per cent of patients (98/1207, 95% CI: 6.7%-9.8%) had active HCV infection and 3% (38/1207, 95% CI: 2.3%-4.3%) past HCV infection. Overall, one quarter (51/205) of people recruited in drug treatment services, 13% (65/491) of people from homeless residential sites and 4% (20/511) prisoners in this study were anti-HCV positive. Seventy-seven of the 136 (56.6%, 95% CI: 47.9%-65%) of HCV infected participants identified had a history of all three risk factors (homelessness, imprisonment and drug use), 27.3% (95% CI: 20.1%-35.6%) had 2 overlapping risk factors, and 15.4% (95% CI: 10.6%-23.7%) one risk factor. Drug treatment services, prisons and homelessness services provide good opportunities for identifying hepatitis C-infected individuals. Effective models need to be developed to ensure case
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| INTRODUC TI ON
Since the discovery of Hepatitis C Virus (HCV) in 1989, the virus has become recognized as the leading cause worldwide of chronic liver disease. Although data on prevalence of HCV in many countries are still not available, the most recent estimate from WHO (World Health Organization) is 1%, representing about 71 million people infected. In high-income countries, the burden of hepatitis C is mainly within marginalized populations such as People Who Inject Drugs (PWID), people who are homeless and prisoners-though it can be difficult to accurately assess disease prevalence. Several studies have estimated the prevalence of hepatitis C in PWID, [2] [3] [4] [5] [6] [7] [8] [9] with fewer studies reporting the prevalence of HCV among prisoners, [10] [11] [12] [13] people who are homeless, [14] [15] [16] [17] and migrants from countries at high risk of HCV. 18 Better estimates, which could support the development of targeted strategies to reduce HCV infection and transmission in these populations, is needed.
A recent national unlinked anonymous survey demonstrated that London had the highest proportion of detectable antibodies to Hepatitis C (anti-HCV prevalence) among PWID. 5 The city also had the most laboratory reports of hepatitis C infection nationally. 19 Further, it has been identified as having the greatest number and proportion of homeless in England-with one in 25 lacking a permanent home. 20 This emphasizes the need for further epidemiological work to characterize the burden of disease among marginalized populations in London.
The recent introduction of Direct-Acting Antiviral (DAA) treatment provides the opportunity to substantially reduce the global burden of hepatitis C. These drugs combine high rates of clinical effectiveness with few treatment side effects-increasing their tolerability. This is of particular importance in vulnerable patients such as PWIDs, the homeless and prisoners, who may be unable to tolerate long-term treatment with the older drugs such as interferon-based therapy. [21] [22] [23] In this study, we sought to estimate the prevalence of, and risk factors for, HCV infection in individuals susceptible to HCV by virtue of being homeless, in contact with drug treatment services or in prison in London.
| ME THODS AND PARTI CIPANTS
| Study population
We undertook a cross-sectional study between May 2011 and June 2013 in London, United Kingdom. This was part of a previously published study where the primary aim was to determine the prevalence of latent tuberculosis infection, though participants were also tested for blood borne viruses. 24 Subjects were recruited from 39 homeless hostels and 20 drug treatment services through the National Health Services Find and Treat (F&T) Service 25 -a specialist outreach team with the main aim of tackling TB in people who are homeless, vulnerable migrants and drug or alcohol users. The service screens almost 10 000 high-risk people every year, covering every London borough. The homeless hostels and drug treatment services recruited in this study were representative of those within the city.
Five hundred and eleven inmates were also recruited from a category B prison (one that does not require maximum security, but with inmates still recognized as being "high risk" and requiring significant security measures to ensure they do not escape) in London by a separate team (of research staff) employed by the study. The physical geography of the prison meant that we were unable to access and recruit many prisoners to this study who were undergoing drug detoxification, as they were located in a separate prison wing.
Patients were eligible for inclusion in the study if they were aged >18 years, had the capacity to consent and were identified as 
| Laboratory testing
Venous blood samples were taken from participants and tested at the Royal Free Hospital for hepatitis C. Anti-HCV antibody was detected using Vitros chemiluminescence assay (Ortho Clinical Diagnostics). HCV-RNA was detected using PCR Assay or Abbott 
| Statistical analysis
From this study, we assessed the proportion of participants who had HCV active (currently infected) and past infection. 
| RE SULTS
A total 1207 participants were recruited during the study period, (Table 2 ).
| HCV infection
In the adjusted analysis, only longer duration of injection drug use
TA B L E 1 Characteristics of participants
Characteristics n HCV-current infection (%) HCV-past infection (%)
Total HCV infection (%) (2-9 years, 10 years or greater), being aged more than 30 years, and UK-born nonwhite ethnicity were strongly associated with HCV infection (though in the latter case as a negative association) ( 
| Risk factors for HCV spontaneous clearance
Thirty-eight out of 136 participants with evidence of past HCV no longer had detectable HCV RNA (28%). In the univariate analy- (Table 3) .
| Risk factors for HCV in those who reported not injecting drugs
| D ISCUSS I ON
This study confirmed the high prevalence of HCV-antibody-positive infection when screening in drug treatment services (25%), homeless services (13%) and prison (4%). The risk in prisoners was likely The use of bold types shows results with statistically significant associations underestimated due to the exclusion of those located in the detoxification wing of the prison who were difficult to access within this study. There was a very high degree of overlap between these three populations. The risk was driven primarily by injecting drug use. Past or active HCV infection was found in 27% of those injecting less than a year, 56% injecting between one and 10 years and 70% for over 10 years compared to 3% of those who reported never having injected. Nevertheless, 20% of past or active HCV infections were in this latter population, and here HCV infection was more likely in older people and those who had alcohol problems, possibly reflecting differential reporting of injecting drug use in these groups.
Twenty-eight per cent of study participants with HCV antibody no longer had detectable HCV RNA suggesting spontaneous clearance (none had been treated). Clearance was least likely in those who reported needle sharing. This supports the hypothesis that spontaneous clearance rates are low in PWIDs because of reinfection.
The strength of our study is that we were able to recruit vul- be affected by recall bias or reluctance to report these risk factors.
Our study results are susceptible to recruitment bias as 60% of participants reported being homeless at least once in their lifetime, and half of it came from those who were recruited from homeless shelters. Although this could potentially affect our estimates, we also examined other risk factors for each vulnerable population.
Missing data were a potential limitation, though given that less of 5% of data were missing, we could adjust for this using pairwise deletion to maximize the data analysis. In addition, information bias might have occurred because the definition of an alcohol problem used in this study was whether participants had ever been concerned about their drinking or had a health worker express concern about their alcohol consumption, thus we could not measure objectively how much alcohol was being consumed or its actual consequences. The use of bold types shows results with statistically significant associations noted though that our study also identified homeless hostels as an important site to screen for HCV as many homeless have a history of injecting drug use, though may not be currently known to drug treatment services.
Our study showed that 13.2% of people who are homeless were infected with HCV. This was similar to work conducted in Oxford in 2002 (26.5%) 34 ; as well as pooled prevalence estimates from a meta-analysis of 43 studies reported in 2012 (20.3%). 35 While we recruited individuals from homeless hostels where the prevalence of PWID was 17.8%, the Oxford study recruited street homeless who
were not in contact with homeless shelters services. These individuals were likely to be even more vulnerable, supported by the fact that more than half of the participants in this study were PWIDs.
This again highlights the importance of intersecting risk factors and provision of better services and access to the service in London.
The study demonstrates that screening homeless people for HCV is worthwhile, but the fact that none of those identified had been treated shows the need for increased efforts to ensure treatment.
As discussed earlier, our study is likely to have underestimated the prevalence of HCV in prison populations (3.9%) because it largely excluded prisoners undergoing drug detoxification. It was low compared to a study conducted in a Scottish prison where the prevalence was 19% 36 or a cross-sectional study in Dartmoor prison where the prevalence was 12.6%. 37 In the Scottish study, 53% of prisoners had injected drugs, whereas in our study only 8.6% of prisoners were PWIDs.
36
Being homeless, PWID and imprisoned may increase vulnerability to infection. For example, Homeless Drug Users (HDUs) have been described as experiencing "double jeopardy" given the large number of life and health issues they encounter. 38 Over half of the individuals in our study had a history of homelessness, drug use and imprisonment. A study in South Wales that recruited participants from treatment services, needle and syringe exchange services, homeless hostels and the streets, showed that being homeless increased the risk of HCV about 4 fold (OR = 4.41, 95% CI: 1.6-12.5).
39
Furthermore, work by Vescio, et al. estimated risk of infection with HCV among inmates who were PWIDs to be 24 times than non-PWID inmates.
40
We found that 50.7% of HCV infected individuals had coinfection with other blood borne viruses (HBV or HIV)-which is likely to be driven by needle sharing behaviour. 41 A study performed in two Spanish prisons showed a high prevalence of HCV-HBV coinfection (42.5%) and HIV-HBV-HCV coinfection (37.3%), with monoinfections being less common (overall 13%). 42 Needle sharing is the major risk for HCV coinfection 41 ; though sexual activity and duration of injection are also associated with HCV-HIV coinfection. 43 6.6% of HCV patients were coinfected with LTBI only (14% had triple infection of HCV and LTBI and HIV/HBV).
Our study suggested injecting drug use with longer duration (2-9 years, 10 years or more) were the strongest risk factors for HCV The specific association between country of birth-ethnicity and HCV infection is not well understood, and may be confounded by other factors such as the prevalence of injecting drug use. In our study, 22% of UK-born white were PWID compared to only 0.1% among UK born nonwhite group. More studies are needed to better explain the racial differences in HCV infection.
Overall, using a convenience sample of participants in specific settings within London, our study provides evidence of a high bur- This study has highlighted the strong association of injecting drug behaviour and its duration with HCV infection. It is important, therefore, to intervene early to minimize risk of transmission.
Given that 20% of hepatitis C infected patients in our study did not report a history of injecting drug use, it seems reasonable to screen in these settings regardless of reported behaviour. The advent of DAAs offers new opportunities to expand treatment but integrated models of screening for blood borne viruses, managing addiction as well as infections need to be developed and evaluated. Future research should focus on how screening, treatment and prevention services can be integrated for vulnerable populations to maximize treatment access and reduce reinfection. The aspiration of eliminating HCV is unlikely to be achieved without such integrated services. 
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